LIVE WEBINAR: Thursday, September 8, 2022, 5:00 PM – 6:00 PM Eastern Time

Exploring Current Considerations and Promising Investigational Approaches for Patients with Myelodysplastic Syndromes

A CME/MOC-Accredited Virtual Event

Join us on Thursday, September 8th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Gail J Roboz, MD
Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

David Sallman, MD
Assistant Member
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Neil Love, MD
Research To Practice
Miami, Florida

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Thursday, September 8, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Current Management Paradigm for Myelodysplastic Syndromes (MDS)
  • MODULE 2: Evaluating the Role in MDS of Therapies with Established Indications for Other Diseases
  • MODULE 3: Novel Agents and Strategies Under Investigation for MDS

Target Audience
This activity is intended for hematologists, hematology-oncology fellows, medical oncologists, radiation oncologists and other healthcare providers involved in the treatment of myelodysplastic syndromes.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recognize the value of molecular testing for patients with myelodysplastic syndromes (MDS), and determine how various genetic alterations may affect MDS classification and risk assessment.
  • Evaluate the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for lower- and higher-risk MDS.
  • Recognize the FDA-approved indication for oral hypomethylating agent therapy for intermediate- and high-risk MDS, and identify patients for whom this novel approach may be appropriate.
  • Describe the biologic rationale for and available research findings with Bcl-2-targeted therapy for patients with high-risk MDS, and appraise the potential role of this strategy in current and future clinical care.
  • Develop an understanding of the mechanisms of action of and available data with investigational therapeutic approaches for higher-risk MDS in order to prepare for their potential availability in routine practice.
  • Implement a plan to manage the side effects associated with approved and investigational therapies for MDS to support quality of life and continuation of treatment.
  • Recall the design of ongoing clinical trials for low- and high-risk MDS, and counsel appropriate patients about the potential benefits of participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation, Support and Credit Statements

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc and Research To Practice. Medical Learning Institute, Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physician Continuing Medical Education
Medical Learning Institute, Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc, is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Dr Garcia-Manero has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr RobozConsulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, bluebird bio, Blueprint Medicines, Bristol-Myers Squibb Company, Catamaran Bio, Celgene Corporation, GlaxoSmithKline, Helsinn Healthcare SA, Janssen Biotech Inc, Jasper Therapeutics Inc, Jazz Pharmaceuticals Inc, Mesoblast, Novartis, Pfizer Inc, Roche Laboratories Inc, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc (IRC Chair); Research Support: Janssen Biotech Inc.
Dr SallmanAdvisory Committee: AvenCell Therapeutics Inc, bluebird bio, Bristol-Myers Squibb Company, Intellia Therapeutics, Jasper Therapeutics Inc, Kite, A Gilead Company, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Affimed GmbH, Gilead Sciences Inc, Intellisphere LLC, Molecular Partners, Precigen Inc, Takeda Pharmaceuticals USA Inc, Zentalis Pharmaceuticals; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Incyte Corporation, Servier Pharmaceuticals LLC.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.

This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.